Latest news
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:00:00 GMTNTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - StocktwitsStocktwits · Fri, 07 Aug 2026 22:50:17 GMTAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Business WireBusiness Wire · Fri, 07 Aug 2026 20:30:00 GMTBioVie stock sinks on Phase IIb Parkinson’s trial data - Clinical Trials ArenaClinical Trials Arena · Fri, 07 Aug 2026 10:14:16 GMTKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - KaryopharmKaryopharm · Thu, 30 Jul 2026 07:00:00 GMTAltimmune drug cuts heavy drinking in mid-stage trial for alcohol use disorder - ReutersReuters · Tue, 28 Jul 2026 07:00:00 GMTProMIS jumps on trial data for Alzheimer’s drug (PMN:NASDAQ) - Seeking AlphaSeeking Alpha · Tue, 28 Jul 2026 07:00:00 GMT